ArticleCNS drugs2026

A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use.

Avia Merenlender Wagner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.